Delphi Ventures

Status

ACTIVE

Global HQ

San Mateo, United States

Countries of investment

Investment stages

Seed
Series A

Industries

Biotechnology
AI
Health Tech

About
Delphi Ventures is dedicated to pioneering the development of monoclonal antibody therapeutics that target a range of complex health conditions, including migraine, Cushing’s disease, Congenital Adrenal Hyperplasia, and various autoimmune and inflammatory disorders. By leveraging its extensive expertise in biopharmaceutical innovation, Delphi Ventures strives to enhance patient outcomes through tailored therapies that address unmet medical needs. The company's commitment to research and development positions it at the forefront of advancing treatment options, contributing to improved quality of life for patients suffering from these challenging conditions.

Min check size: $100K
Max check size: $10M
Fund size: Unlock
NPS: Unlock

Investment Thesis

They leverage our passion, expertise, deep experience and network to help advance new technologies and build market leading companies. Delphi has helped several drugs achieve market approval. The firm has enabled dozens of companies to expand therapeutic access for patients who need less invasive procedures.

Lead investor: Unlock
Co Invest: Unlock
Number of exits: Unlock
Preferred contact method: Unlock

Manager's Experience

With extensive experience in venture capital, the fund manager has actively engaged in over 50 deals across sectors such as technology, healthcare, and consumer products. Their strategic approach combines a data-driven investment style with a strong focus on early-stage companies in North America and Europe. Noteworthy exits include successful acquisitions that have significantly contributed to their portfolio's growth. The manager emphasizes thematic investing, targeting emerging trends to maximize returns and drive innovation.